Testing BKPyV-specific T cells by ELISpot before and 2 months after transplantation should be a reliable marker for stratifying its risk, and the use of mTOR inhibitors could protect against BKPyV-nephropathy. The gene discussed is MTOR; the disease is Nephropathy.